<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528785</url>
  </required_header>
  <id_info>
    <org_study_id>CRC2017_01</org_study_id>
    <nct_id>NCT03528785</nct_id>
  </id_info>
  <brief_title>A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer</brief_title>
  <acronym>nITRo</acronym>
  <official_title>A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer &quot;nITRo Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Ricerche Cliniche di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Ricerche Cliniche di Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rational:Pancreatic cancer is a systemic disease at the time of diagnosis, even among&#xD;
      patients with apparent localized disease. Surgical resection is the only potentially curative&#xD;
      therapy for pancreatic cancer, but in patients who undergo surgery and postoperative therapy,&#xD;
      metastatic relapse remains common and no more than 20% of patients achieve 5-year survival.&#xD;
&#xD;
      Because of this aggressive biologic behavior, an increasing interest is growing about&#xD;
      preoperative treatments in resectable pancreatic cancer.&#xD;
&#xD;
      The combination chemotherapeutic regimen with irinotecan + 5-fluorouracil (5-FU)/leucovorin&#xD;
      (LV) + oxaliplatin (FOLFIRINOX) is an effective choice for first line treatment in patients&#xD;
      affected by advanced pancreatic cancer, and in this setting it achieved a Disease Control&#xD;
      Rate of 70.2 % (10). In this regard, FOLFIRINOX is currently explored as preoperative regimen&#xD;
      in a number of clinical trials in resectable pancreatic cancer.&#xD;
&#xD;
      A critical challenge in this field remains the introduction in these combination treatments&#xD;
      of the most novel and effective agents such as nalIRI, in order to obtain a more profound&#xD;
      tumor shrinkage, to increase the rate of R0 resections, to allow an early treatment of occult&#xD;
      micrometastatic disease, and eventually, to improve survival in patients with resectable&#xD;
      pancreatic cancer.&#xD;
&#xD;
      This study proposal is designed to address this challenge. Preliminary results, collected&#xD;
      during the Part 1 Dose Escalation of a current clinical trial performed in mPDAC, show that&#xD;
      dose of nal-IRI: 60 mg/m2, Oxaliplatin: 60 mg/m2, 5-FU/LV: 2400/400 mg/m2 is safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to determine the proportion of patients affected by resectable pancreatic&#xD;
      cancer who achieve R0 resection after a perioperative 6-cycle chemotherapy, 3 pre- and 3&#xD;
      post-surgery, in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      All patients in the program will be identified by a unique identifier number assigned&#xD;
      sequentially.&#xD;
&#xD;
      Patients will receive a treatment scheme of nal-IRI, oxaliplatin, Levofolinic Acid and&#xD;
      5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.&#xD;
&#xD;
      C1D1 is a fixed day, C1D15 and Day 1 and Day 15 of all subsequent cycles should be performed&#xD;
      with a window of ± 2 days.&#xD;
&#xD;
      Patients achieving stable disease or better will undergo pancreatectomy 4-8 weeks after&#xD;
      completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy,&#xD;
      patients will receive an additional 3 cycles of nal-IRI, oxaliplatin, Levofolinic Acid and&#xD;
      5-fluorouracil (5 -FU) treatment in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Tumor responses will be assessed after 3 cycles of preoperative treatment and after 3 cycles&#xD;
      of postoperative treatment or sooner if the treating physician suspects disease progression&#xD;
      based on clinical signs and symptoms. All treatment decisions will be based on the local&#xD;
      radiologist and/or treating physician assessment of disease status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)</measure>
    <time_frame>4-8 weeks after the completion of 3 courses of treatment</time_frame>
    <description>Number of patients achieving R0 resection after preoperative nanoliposomal irinotecan (nal-IRI), Oxaliplatin, Leucovorin (LV), 5-FluoroUracil (5-FU)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine 2-year overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>(OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine disease-free survival (DFS)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>(DFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimate frequency and severity of adverse events associated with chemotherapy</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine overall response rate (ORR) following preoperative chemotherapy</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimate proportion of patients going to surgery for resection after preoperative chemotherapy</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>estimate proportion of patients going to surgery for resection after preoperative chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimate pathologic response rate (pCR)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>(pCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess lymph node status</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>assess lymph node status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess surgical mortality</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>assess surgical mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess surgical morbidity</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>assess surgical morbidity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid</intervention_name>
    <description>Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle&#xD;
Irinotecan Liposomal Injection [Onivyde] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle&#xD;
Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle&#xD;
5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and provide written informed consent.&#xD;
&#xD;
          2. ≥ 18 years of age.&#xD;
&#xD;
          3. Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas.&#xD;
&#xD;
          4. Patients must have measurable disease in the pancreas, with no evidence of metastatic&#xD;
             disease on imaging of the chest, abdomen and pelvis (contrast-enhanced CT or MRI&#xD;
             abdomen with contrast instead of abdominal CT); PET scans alone will not be adequate&#xD;
             alternatives.&#xD;
&#xD;
          5. The primary tumor must be surgically resectable, defined as:&#xD;
&#xD;
               1. no involvement (abutment or encasement) of the major arteries (celiac, common&#xD;
                  hepatic and/or superior mesenteric artery);&#xD;
&#xD;
               2. no involvement or &lt;180° interface between tumor and vessel wall of the portal&#xD;
                  vein, superior mesenteric vein and/or portal vein/splenic vein confluence.&#xD;
&#xD;
          6. Adequate hepatic, renal and hematological function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum total bilirubin ≥2 x ULN (biliary drainage is allowed for biliary obstruction).&#xD;
&#xD;
          2. Severe renal impairment (CLcr ≤ 30 ml/min).&#xD;
&#xD;
          3. Inadequate bone marrow reserves as evidenced by:&#xD;
&#xD;
          4. ANC ≤ 1,500 cells/μl; or Platelet count ≤ 100,000 cells/μl; or Hemoglobin ≤ 9 g/dL&#xD;
&#xD;
          5. KPS &lt; 60&#xD;
&#xD;
          6. Patients who received previous chemotherapy or radiotherapy for pancreatic disease.&#xD;
&#xD;
          7. Any clinically significant disorder impacting the risk-benefit balance negatively per&#xD;
             physician's judgment.&#xD;
&#xD;
          8. Any clinically significant gastrointestinal disorder, including hepatic disorders,&#xD;
             bleeding, inflammation, occlusion, or diarrhea &gt; grade 2.&#xD;
&#xD;
          9. Severe arterial thromboembolic events (myocardial infarction, unstable angina&#xD;
             pectoris, stroke) in last 6 months.&#xD;
&#xD;
         10. NYHA Class III or IV congestive heart failure, ventricular&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stefano milleri, Dr</last_name>
    <role>Study Director</role>
    <affiliation>centro ricerche cliniche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>stefano Milleri, Dr</last_name>
    <phone>+390458126619</phone>
    <email>stefano.milleri@crc.vr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Ricerche Cliniche</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Milleri, Dr.</last_name>
      <phone>+390458126619</phone>
      <email>stefano.milleri@crc.vr.it</email>
    </contact>
    <contact_backup>
      <last_name>Giorgia Barbiero, Dr.</last_name>
      <phone>+390458126562</phone>
      <email>giorgia.barbiero@crc.vr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Davide Melisi, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Adenocarcinoma</keyword>
  <keyword>Liposomial IrinoTecan</keyword>
  <keyword>nal-IRI</keyword>
  <keyword>Resectable pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPDs published</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

